The Unresolved Problem in PNH: Why C5 Inhibition Was Never Enough

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening clonal disorder of hematopoietic stem cells in which a somatic mutation in the PIG-A gene causes deficiency of GPI-anchored complement regulatory proteins — most critically CD55 and CD59 — leaving red blood cells, white blood cells, and platelets vulnerable to uncontrolled complement-mediated destruction. The disease manifests as hemolytic anemia, thrombosis, and bone marrow failure, and before the era of complement inhibition, median survival was measured in years.

The introduction of eculizumab in 2007 — a monoclonal antibody targeting terminal complement protein C5, developed by Alexion — represented a genuine paradigm shift. By blocking C5 cleavage, eculizumab prevented the formation of the membrane attack complex (MAC) and dramatically reduced intravascular hemolysis, thrombotic events, and mortality. Ravulizumab, a long-acting C5 inhibitor with an extended half-life enabling every-eight-week dosing, followed as a more convenient successor. According to FDA labelling data, both agents substantially reduce lactate dehydrogenase (LDH) — a marker of intravascular hemolysis — in the majority of treated patients.

Yet a clinically significant problem persisted. C5 inhibitors block only the terminal complement pathway. When C5 cleavage is blocked, complement activation continues upstream, and C3b-opsonised red blood cells are cleared by macrophages in the spleen and liver — a process known as extravascular hemolysis (EVH). In a meaningful proportion of patients on anti-C5 therapy, persistent anaemia, fatigue, and transfusion dependence continued, not from intravascular lysis, but from this EVH mechanism. This unmet need — anaemia despite C5 inhibition — became the central target for the next generation of complement inhibitors.

How Iptacopan Targets Factor B to Block the Alternative Pathway

Iptacopan (development code LNP023; brand name Fabhalta) is an oral, small-molecule inhibitor of complement Factor B — a serine protease that is the catalytic subunit of the alternative pathway C3 convertase (C3bBb). Factor B is uniquely positioned in the complement cascade: it is required for the assembly and activity of both the initial C3 convertase and the amplification loop that accounts for the majority of total complement activation across all three pathways (classical, lectin, and alternative). By occupying the active site of Factor B and preventing its cleavage by Factor D, iptacopan halts the amplification loop at its origin.

The mechanistic consequence is comprehensive: by preventing C3b deposition on PNH red blood cells, iptacopan eliminates both the terminal complement-mediated intravascular destruction that eculizumab and ravulizumab address, and the C3b-mediated extravascular destruction that they do not. This dual coverage is the pharmacological basis for the superior haemoglobin responses observed in clinical trials. According to regulatory filings reviewed by the European Medicines Agency (EMA), iptacopan received a positive opinion for PNH in the European Union in 2024, with the EMA’s Committee for Medicinal Products for Human Use (CHMP) citing the Factor B mechanism as enabling a clinically meaningful improvement over existing C5 inhibitor therapy.

Iptacopan is administered orally as a 200 mg capsule taken twice daily — a stark contrast to ravulizumab’s intravenous infusion every eight weeks and pegcetacoplan’s subcutaneous self-injection twice weekly. The oral route eliminates infusion-related reactions, removes the requirement for hospital or clinic visits for drug administration, and removes the need for prophylactic meningococcal vaccination that is mandatory with anti-C5 biologics due to the risk of encapsulated bacterial infections from terminal complement blockade. While iptacopan’s proximal mechanism does raise theoretical concerns about susceptibility to certain infections, the clinical trial programme did not identify a comparable infection signal to that seen with C5 inhibitors.

APPLY-PNH Trial: Superiority Over Anti-C5 Therapy in Numbers

The APPLY-PNH Phase 3 trial enrolled adult PNH patients who had residual anaemia (haemoglobin below 10 g/dL) despite stable anti-C5 therapy with eculizumab or ravulizumab for at least six months — precisely the population experiencing extravascular hemolysis not addressed by C5 inhibition. Patients were randomised to iptacopan monotherapy 200 mg twice daily or to continue their existing anti-C5 regimen.

The co-primary endpoints were: (1) proportion of patients achieving a sustained haemoglobin increase of ≥2 g/dL from baseline, and (2) proportion achieving transfusion avoidance. On both endpoints, iptacopan was statistically superior to continued anti-C5 therapy. The 82% haemoglobin responder rate and 94% transfusion independence rate in the iptacopan arm versus 2% and 66%, respectively, in the anti-C5 continuation arm represented a magnitude of difference that the FDA considered clinically meaningful and that formed the basis for the December 2023 approval of Fabhalta for adults with PNH.

Secondary endpoints reinforced the primary findings. Mean haemoglobin levels increased from approximately 8.7 g/dL at baseline to above 11 g/dL by week 24 in the iptacopan arm, while remaining essentially unchanged in the anti-C5 continuation arm. LDH levels — the established biomarker of intravascular hemolysis — remained controlled in both arms, confirming that iptacopan’s Factor B blockade did not compromise control of terminal complement-mediated intravascular lysis while simultaneously resolving the extravascular component.

“Iptacopan achieved a haemoglobin increase of ≥2 g/dL in 82% of patients previously treated with anti-C5 therapy — compared to 2% of patients who continued anti-C5 treatment — a result that redefines the efficacy benchmark in PNH.”

The APPLY-PNH safety profile was consistent with the mechanism of action. No cases of meningococcal infection — the most serious safety concern with terminal complement inhibitors — were reported. The most common adverse events were headache, diarrhoea, and nasopharyngitis, all of low-to-moderate severity. The absence of infusion reactions (compared to IV biologics) and injection site reactions (compared to pegcetacoplan) was noted as a favourable tolerability characteristic in the FDA review documents.

Ravulizumab, Pegcetacoplan, and the Oral Complement Shift

The approval of iptacopan reshapes a PNH treatment market that had been defined for fifteen years by intravenous C5 inhibition. Understanding the competitive implications requires mapping each agent against three axes: mechanism (distal vs. proximal complement blockade), route of administration, and the patient populations in which each is positioned.

Ravulizumab (Ultomiris), developed by Alexion/AstraZeneca, is the dominant C5 inhibitor in PNH, having largely displaced eculizumab due to its extended dosing interval. It remains highly effective at controlling intravascular hemolysis and preventing thrombosis, and its safety profile — including the meningococcal infection risk managed by vaccination — is well-characterised across thousands of patient-years of exposure. For patients with well-controlled haemoglobin on ravulizumab, the clinical rationale for switching to iptacopan is less compelling; however, for the estimated 30–40% of patients on C5 inhibitors who experience residual anaemia attributable to EVH, iptacopan represents a mechanistically superior option, as documented in publications reviewed by The New England Journal of Medicine.

Pegcetacoplan (Empaveli in the US, Aspaveli in Europe), developed by Apellis Pharmaceuticals, was the first proximal complement inhibitor approved for PNH (May 2021, FDA). As a C3 inhibitor, it acts downstream of Factor B but upstream of C5, blocking the cleavage of C3 and thereby preventing both C3b opsonisation (EVH) and MAC formation (IVH). In the PEGASUS Phase 3 trial, pegcetacoplan demonstrated superiority over eculizumab in haemoglobin response in patients with residual anaemia. The critical differentiator from iptacopan is route of administration: pegcetacoplan requires subcutaneous self-injection twice weekly (or three times per week in some patients), which introduces a meaningful injection burden and requires training for self-administration.

The commercial positioning of iptacopan is therefore most directly competitive with pegcetacoplan in the proximal complement space, and with anti-C5 agents in the broader newly-diagnosed PNH population. Novartis has positioned Fabhalta as a first-line option for treatment-naïve patients in the APPOINT-PNH trial — a separate Phase 3 study in complement-inhibitor-naïve patients — which demonstrated that iptacopan monotherapy maintained haemoglobin above 12 g/dL in the majority of patients and achieved transfusion independence in over 95% of the study population. This data, submitted to the FDA and EMA, supports a potential label expansion beyond the current indication in anti-C5-experienced patients.

Patent Landscape and Innovation Signals in Complement Inhibition

The commercial approval of iptacopan sits atop a substantial patent estate protecting the Factor B inhibitor scaffold, its synthesis, formulation, and therapeutic applications. Novartis’s foundational patents covering the LNP023 compound and its use in complement-mediated diseases were filed in the early 2010s and provide protection extending into the 2030s in major markets, giving Fabhalta a commercially defensible exclusivity window during the peak of its anticipated market uptake in PNH and potentially in additional complement-mediated indications.

The broader complement inhibitor patent landscape has seen a significant acceleration in filing activity over the 2015–2024 period, driven by the validation of complement as a tractable therapeutic target across multiple disease areas — including PNH, IgA nephropathy, C3 glomerulopathy, geographic atrophy, and systemic lupus erythematosus. According to data tracked on the WIPO PatentScope database, complement pathway inhibitor filings have grown substantially year-on-year, with Factor B, Factor D, and C3 inhibitors accounting for an increasing share of new filings relative to the historically dominant C5 antibody space.

The competitive patent environment for oral small-molecule complement inhibitors is particularly active. Several programmes targeting Factor D (danicopan, vemircopan), C3 (systemic and local), and novel targets such as properdin and MASP-2 have generated substantial IP activity from companies including Omeros, BioCryst, Apellis, and multiple Chinese and Japanese generic/specialty pharma entrants. The European Patent Office (EPO) has published a growing number of opposition proceedings against complement inhibitor patents, reflecting the commercial value at stake and the intensity of competition in this space. For R&D teams and IP strategists, mapping the freedom-to-operate landscape around Factor B inhibitors — including Novartis’s core claims and the design-around space — is a critical input to pipeline prioritisation.

PatSnap Eureka’s drug intelligence platform aggregates patent filings, clinical trial registrations, regulatory submissions, and literature across the complement inhibitor landscape, enabling IP professionals and drug developers to identify white spaces, monitor competitor activity, and assess the validity and scope of foundational patents in real time. With over 2 billion data points across 120+ countries, the platform provides the granularity required to navigate a patent environment as technically complex and commercially consequential as the PNH complement space.